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Endothelial dysfunction is characterized by reduced bioavailability of NO due to its inactivation to form peroxynitrite or reduced
expression of eNOS. Here, we examine the causal role of peroxynitrite in mediating diabetes-induced endothelial dysfunction.
Diabetes was induced by STZ-injection, and rats received the peroxynitrite decomposition catalyst (FeTTPs, 15mg/Kg/day)
for 4 weeks. Vasorelaxation to acetylcholine, oxidative-stress markers, RhoA activity, and eNOS expression were determined.
Diabetic coronary arteries showed signiﬁcant reduction in ACh-mediated maximal relaxation compared to controls. Diabetic
vessels showed also signiﬁcant increases in lipid-peroxides, nitrotyrosine, and active RhoA and 50% reduction in eNOS mRNA
expression. Treatment of diabetic animals with FeTTPS blocked these eﬀects. Studies in aortic endothelial cells show that high
glucose or peroxynitrite increases the active RhoA kinase levels and decreases eNOS expression and NO levels, which were reversed
withblocking peroxynitrite or Rhokinase. Together, peroxynitrite can suppress eNOS expression via activation of RhoAand hence
cause vascular dysfunction.
1.Introduction
Diabetes mellitus predisposes patients to premature athero-
sclerotic coronary artery disease, the leading cause of mor-
bidity and mortality among patients with diabetes [1, 2].
The vascular endothelium is a target of the diabetic milieu,
and endothelial dysfunction has been thought to play a
central role in diabetic vascular diseases (reviewed in [3]).
Diabetes-inducedendothelialdysfunctionischaracterizedby
reduced bioavailability of nitric oxide (NO) in the vessel
wall. NO, a major regulator of vascular tone, is produced by
the activity of endothelial NO synthase (eNOS). Diminished
capacity of eNOS to generate NO has been demonstrated
whenendothelialcellswereexposedtoelevatedglucoselevels
either in vitro or in vivo [4–7]. In response to hyperglycemia,
an imbalance between increased production of superoxide
anion (O2
.−) and NO drives the formation of peroxynitrite
(ONOO−) within the vascular wall [8]. Peroxynitrite can
oxidize the NOS cofactor tetrahydrobiopterin and also
reduce cellular transport of L-arginine, eNOS substrate for
NO production [9]. These events uncouple the enzyme,
which then preferentially increases O2
.− production over
NO production leading to a vicious cycle of peroxynitrite
formation and further inactivation of NO [4, 10].
Recent studies raised the possibility that diabetes-
impaired NO bioavailability could be caused by reduced
expression of eNOS, in addition to the known role of O2
.− to
inactivateNO[11–13].Accumulatingevidenceindicatesthat2 Experimental Diabetes Research
expressionofeNOSisregulatedbytheRhoA/ROCKpathway
[14, 15]. The small GTP-binding protein RhoA GTPase and
its downstream target, the Rho-associated kinase (ROCK),
are implicated in a variety of physiological functions of
endothelial cells including cell adhesion, motility, migration,
and contraction [16]. Inhibition of the RhoA/ROCK path-
way indirectly by statins or directly by ROCK inhibitors
or dominant-negative mutant of RhoA has been shown to
increase eNOS expression [17–19]. Our previous studies
demonstrated signiﬁcant upregulation of the active RhoA
that positively correlated with increases in peroxynitrite as
well as vascular permeability and impaired vasorelaxation
in models of experimental diabetes [20, 21]. However, the
causal role of peroxynitrite in mediating diabetes-induced
endothelial dysfunction and the potential vascular protective
eﬀects of the peroxynitrite decomposition catalyst, FeTTPs,
have not been elucidated. Our goal is to examine the eﬀects
ofdecomposingperoxynitriteandtoexplorethepossiblerole
of RhoA in modulating eNOS expression in rat vessels and
cultured aortic endothelial cells in response to diabetes and
hyperglycemia, respectively.
2.MaterialandMethods
2.1. Animal Preparation. A l lp r o c e d u r e sw i t ha n i m a l sw e r e
performed according to the “Principles of Laboratory Ani-
malCare”(NIHpublicationno.85023,revised1985)andthe
guidelines of the VA Medical Center and Medical College of
Georgia Animal Care and Use Committees. Male Sprague-
Dawley rats (∼250g body weight) were randomly assigned
to: control, treated-control, diabetic, or treated-diabetic
groups. Three sets of animals were prepared (totaling 62
rats) to study the eﬀects of 4 weeks of experimental diabetes.
Diabetes was induced by intravenous tail-vein injection of
streptozotosin (65mg/kg). After 48 hours, diabetic status
was determined by urine detection of glucose. Diabetes
was conﬁrmed with blood-glucose levels >350mg/dl, which
correspond to average blood levels of poorly-controlled
diabetic patients. The animals were treated with the perox-
ynitrite decomposition catalyst, FeTPPs [5,10,15,20-tetrakis
(4-sulfonatophenyl) porphyrinato iron (III)] (Calbiochem,
CA), via intraperitoneal, (IP) injections at 15mg/kg. FeTPPs
exhibits minimal SOD mimetic activity, does not complex
with nitric oxide, and catalytically isomerizes peroxynitrite
to nitrate. After 4 weeks of diabetes, animals were sacriﬁced,
and vessels were isolated for analyses.
2.2. Preparation of Rat Coronary Arteries. Rats were anes-
thetized with intraperitoneal injection of ketamine HCl
(20mg/kg) and xylazine (4mg/kg). A thoracotomy was
performed;heartandthoracicaortawerequicklyexcisedand
placed in ice-cold oxygenated Krebs-Henseleit buﬀer. After
the right ventricle and anterior wall of the left ventricle were
removed under a stereomicroscope, intramyocardial second-
order branches of the septal arteries were dissected from the
septum facing the right ventricular cavity. Arterial segments
(∼2mm long) were gently excised, transferred to the cham-
ber of a small vessel myograph (Danish Myo Technology)
containing 5ml buﬀe r ,a n dm o u n t e do nt u n g s t e nw i r e s
(diameter 40μm). The arteries were allowed to equilibrate
in oxygenated (95% O2–5% CO2) Krebs-Henseleit buﬀer.
The composition of the buﬀer is (in mM) 118.3NaCl,
4.7KCl, 1.2MgSO4, 1.2KH2PO4, 25NaHCO3, 2.5CaCl2,
and 11.0 glucose. Vessels were allowed to stabilize for
30min in the Krebs-Henseleit buﬀer under zero tension,
during that time the buﬀer solution was changed at 10min
intervals. The vessels were then radially stretched to their
optimal lumen diameter for active tension development,
that is, to an internal circumference equal to 90% of that
achieved in vessels exposed to a passive tension equivalent
to a transmural pressure of 100mmHg. Isometric force was
recorded on a computer by use of Chart v 5 software and a
MacLab/4e data acquisition system (AD Instruments).
2.3. Protocol for Acetylcholine Dose-Response Curves. After
the equilibration period, the responsiveness of each individ-
ual artery was conﬁrmed by its successive vasoconstrictive
response to a submaximally concentration of KCl (125mM).
The integrity of the vascular endothelium was tested phar-
macologically by acetylcholine-induced relaxation of arteries
that had been precontracted with U46619 (thromboxane A2
receptor agonist). Tissues that did not elicit a reproducible
and stable contraction with U46619 (1μM) and relaxed
>40% in response to 10μM acetylcholine were discarded
from the study. Preparations were then washed three times
with K-H buﬀer and allowed to relax fully for 30min before
the experimental protocol began. Coronary arteries were
then again precontracted with U46619 at a submaximal
dose of 1μM( Emax,1 0 μM). After reaching a plateau
of contraction, cumulative concentration-response curves
to acetylcholine (ACh, 0.1nM–100μM) were obtained to
evaluate endothelium dependent vasorelaxation. The con-
centration in the chamber was increased in 1-log steps. In all
cases, ACh was added to yield the next higher concentration
only when the response to the earlier dose reached a steady
state. The vasorelaxant responses are expressed as percent
decrease from U-46619-induced contraction; that is, the
amount of contraction produced by 1μM U-46619 in each
vessel from its initial resting tension was considered to be
100%.
2.4. Determination of Nitrotyrosine. Slot-blot analysis was
used to verify the eﬃcacy of FeTPPs of blocking tyro-
sine nitration in treated animals. As described previously
[22, 23], 30μg of aortic homogenate from rat samples
was immobilized onto a nitrocellulose membrane. After
blocking, membranes were reacted with antibody against
nitrotyrosine(Calbiochem),followedbysecondaryantibody,
andenhancedchemiluminescence(GEHealthCare),andthe
optical density of various samples was compared with that of
controls.
2.5. Determination of Lipid Peroxides. The assay was per-
formed on aortic lysates as described before [22]. Brieﬂy,
aortic lysate is reacted with 20% acetic acid, 8% SDS, and
thiobarbituric acid at 95◦C for 60min, and the reaction
was cooled down on ice. The samples were centrifuged, and
the supernatant was extracted with n-butanol and pyridineExperimental Diabetes Research 3
(15:1, resp.), and the absorbance of the organic solvent layer
was measured at 532nm. The results were compared with
an external standard (Tetramethoxypropane). The Bradford
assay (Bio-Rad, Hercules, CA) was performed to determine
the protein concentration of the retinal lysate. Lipid peroxide
level was expressed in nmol MDA/mg total protein.
2.6. Preparation of mRNA and eNOS Expression. Aortic
endothelium mRNA was prepared according to manufac-
turer’s instructions using a Promega kit. The One-step qRT-
PCR Invitrogen kit was used to amplify 10ng of mRNA
from each sample. A pair of rat-speciﬁc eNOS primers was
synthesized to amplify a 123-bp DNA fragment forward-
primer 5 -TGACCCTCACCGATACAACA and reverse-
primer 5 -AACGTGGCTGTGCTGTACAG. The Rat 18-S
was used as an internal marker for each sample. Forward-
primer: CGCGGTTCTATTTTGTTGGT and the reverse-
primer: AGTCGGCATCGTTTATGGTC. Quantitative PCR
was performed using a Realplex Mastercycler (Eppendorf,
NY). Expression of eNOS was normalized to 18S level in
eachsampleandexpressedasrelativeexpressiontountreated
controls.
2.7. Cell Culture Studies. Primary cultures of bovine aortic
endothelial (BAE) cells were prepared as described previ-
ously in [24]. Cells from passages 4–8 were used in all
experiments. Cells were maintained in M199 supplemented
with 10% FBS, 10% CS-C complete medium, 2mM glu-
tamine, 100U/ml penicillin, and 100μg/ml streptomycin at
37◦C in a humidiﬁed CO2 incubator. Cells were incubated
i n5 . 5m M( n o r m a l )o r2 5m M( h i g h )D - g l u c o s ef o r3d a y s
withandwithoutFeTPPs(2.5μM)ortreatedwithexogenous
peroxynitrite 100μM for 18 hours.
2.8. Determination of Oxidative Stress Using DCF Assay.
The oxidation of 2,7-dihydrodichloroﬂurescein diacetate
(DHCF) from Molecular Probes (Eugene, OR) was used.
DCF is the oxidation product of DHCF and is widely used as
a general marker of cellular oxidation by hydroxyl radicals,
hydrogen peroxide, and peroxynitrite. The cultures were
treated with DHCF (5μM) for 1h in the presence or absence
oftheperoxynitritedecompositioncatalystFeTPPs(2.5μM),
and the ﬂuorescence was measured at excitation 495 and
emission 520.
2.9. Western Blot. For analysis of eNOS, aortic endothelial
cells were homogenized in a modiﬁed RIPA buﬀer [20mM
Tris-HCl (pH 7.4), 2.5mM ethylenediamine tetraacetic acid,
50mM NaF, 10mM Na4P2O7, 1% Triton X-100, 0.1%
sodium dodecyl sulfate, 1% sodium deoxycholate, and 1mM
phenylmethyl sulfonyl ﬂuoride]. Total protein concentra-
tions were measured using Bio-Rad protein assay. Protein
samples (40μg) were separated by 7.5% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to
nitrocellulose membrane, and probed with anti- eNOS (Cell
Signaling)andactin(Sigma)followedbysecondaryantibody
and enhanced chemiluminescence (GE Health Care). The
ﬁlms were subsequently scanned, and band intensity was
quantiﬁed using densitometry software (alphEaseFC) and
expressed as relative optical density (ROD).
2.10.RhoAActivity. RhoAactivitywasassessedbypull-down
assay as previously described in [20]. In brief, aortas were
homogenized in assay buﬀer (50mM Tris, pH 7.2; 1% Triton
X-100;0.5%sodiumdeoxycholate;0.1%SDS;500mMNaCl;
10mM MgCl2 and protease inhibitors). Next, 200μgo f
homogenate was incubated with 10μg of agarose (GST)-
TRBD beads at 4◦C for 60min. The beads were washed four
times with the assay buﬀer. Bound Rho proteins were then
detected by Western blot by using a monoclonal antibody
against RhoA (Millipore).
2.11. Nitric Oxide Assay. For analysis of NO formation
in vitro, we used an NO analyzer (Sievers). BAEC in 24-
well plates were incubated in 5.5mM (normal) or 25mM
(high) D-glucose with and without simvastatin (1μM).
After 3 days, media were processed for the measurement
of nitrite (NO
−
2), the stable breakdown product of NO
in aqueous solution, by NO-speciﬁc analyzer. Media were
deproteinized, and samples containing NO
−
2 were reﬂuxed
in glacial acetic acid containing sodium iodide. Under
these conditions, NO
−
2 was quantitatively reduced to NO,
which was quantiﬁed by a chemiluminescence detector after
reaction with ozone in the NO analyzer.
2.12. Data Analysis. All values are shown as mean ±
SEM. Maximal relaxation (Emax) and half-maximal eﬀective
dose (EC50) were calculated from individual dose-response
curves. EC50 values were derived using Graph-Pad Prism.
Diﬀerences among experimental groups were evaluated by
ANOVA, and the signiﬁcance of diﬀerences between groups
was assessed by the post hoc test (Fisher’s PLSD) when
indicated. Signiﬁcance was deﬁned as P<. 05.
3. Results
3.1. FeTPPs Did Not Alter Body Weight or Blood Glucose
Level. Asshownbefore,treatmentwithFeTPPshadno eﬀect
on body weight or blood glucose levels in diabetic rats
[22]. STZ-injected animals had signiﬁcant increases of blood
glucose level (480 ± 24mg/dL) compared to control rats
(185 ±14mg/dL).TreatmentwithFeTPPshadnosigniﬁcant
eﬀect on the blood glucose levels in diabetic rats (567 ±
29mg/dL) or in treated controls (179 ± 12mg/dL).
3.2. FeTPPs Improves Diabetes-Impaired Coronary Endothe-
lial-Dependent Vasorelaxation. We studied the eﬀect of dia-
betes on coronary endothelial-dependent vasorelaxation by
performing ACh concentration-response curves with coro-
nary arteries from diabetic and age-matched control rats. As
shown in Figure 1, ACh produced concentration-dependent
vasorelaxation in coronary arteries from all groups. ACh
producedmaximalrelaxation(Emax)of81%±2.5incoronary
arteries from control rats with an EC50 value of 42 ±
0.15nM. However, coronary arteries from 4 weeks diabetic
rats exhibited decreased Emax to ACh (34.7% ± 3.2) and
a shift in the concentration response curve to the right4 Experimental Diabetes Research
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Figure 1: FeTPPs improves diabetes-impaired coronary endothe-
lial-dependent vasorelaxation. Concentration-response curves for
the eﬀect of ACh for coronary arteries from control, diabetic,
FeTPPs-treated control, and FeTPPs-treated diabetic rats at 4 weeks
(n = 6 in each group). ACh Emax value from diabetic vessels
was signiﬁcantly lower than control. Cotreatment with FeTPPs
improved Emax value from diabetic vessels but did not aﬀect treated
controls. Values are expressed as means ± SEM,
∗P <. 05 versus
control.
with an EC50 value of 94 ± 0.2nM. Treatment with FeTPPs
signiﬁcantlyimprovedEmax relaxationtoAChto58.8%±2.8,
andEC50 wasdecreasedto70 ±1.3nM(Figure 1).Treatment
of controls with FeTPPs did not alter the response to ACh.
Coronary arteries from various groups relaxed in a similar
fashion to the NO donor SNP as shown in our previous
studies [6, 20]. These data conﬁrmed that, in our model,
diabetes impairs endothelial-dependent-relaxation only and
has no eﬀect on smooth muscle relaxation.
3.3. FeTPPs Blocked Diabetes-Induced Oxidative Stress and
Nitrotyrosine Formation in Rat Vessels. Diabetes-induced
oxidative stress was analyzed by measuring lipid peroxides
and nitrotyrosine in aorta homogenate from various groups.
The results showed that diabetes causes signiﬁcant increases
(1.5 fold) in lipid peroxides as well as tyrosine nitration (1.4
fold) compared to control animals. Treatment of diabetic
rats with FeTPPs (15mg/Kg/day) signiﬁcantly reduced lipid
peroxidation and nitrotyrosine formation in diabetic vessels
to control levels (Figures 2(a) and 2(b)).
3.4. FeTPPs Blocked High-Glucose-Increased ROS Formation
in BAEC. In order to further deﬁne the impact of the
diabetic milieu on the vascular endothelium, we determined
the eﬀect of high glucose on ROS produced by bovine aortic
endothelial cells (BAEC) using the oxidized dichloroﬂuo-
rescein ﬂuorescence (DCF), a commonly used marker for
both oxidative and nitrative stress. The results showed that
incubation with 25mM glucose for 3 days caused an increase
in ROS formation of ∼58% above controls. Concurrent
treatment with the speciﬁc peroxynitrite decomposition
catalyst FeTPPs (2.5μM) completely blocked high glucose-
induced ROS formation (Figure 2(c)). These results suggest
that peroxynitrite is the major free radical produced by high
glucose treatment.
3.5. FeTPPs Restored Nitric Oxide Production in Diabetic
Vessels. Inordertotestwhethertheincreasedoxidativestress
in diabetic rats reduces NO availability, we determined NO
formation using a NO analyzer. As shown in Figure 3(a),
diabetes signiﬁcantly reduced NO production by 50% below
control level. Cotreatment of diabetic animals with FeTPPs
(15mg/Kg/day) prevented the reduction in NO production
to control levels.
3.6. FeTPPs Restored eNOS Expression in Diabetic Vessels.
In order to determine whether FeTPPs improves NO pro-
duction through altering eNOS expression, we measured
eNOS mRNA levels from isolated rat aortic endothelium
from various groups. Diabetes signiﬁcantly reduced eNOS
expression (54% of basal level) in aortic endothelium
compared to controls (Figure 3(b)). Treatment of diabetic
animals with FeTPPs restored eNOS back to 87% of basal
level. These data suggest that FeTPPs improved endothelial
dysfunction via a mechanism that involves an action of
inhibiting the reduction of eNOS expression.
3.7. FeTPPs Inhibited Activation of RhoA in Diabetic Ves-
sels and High-Glucose-Treated BAEC. Activation of small
GTPases such as RhoA has been shown to modulate eNOS
expression at the mRNA level. Therefore, we measured the
levels of active RhoA in aortic endothelial homogenate from
various groups. The results showed that diabetes causes
signiﬁcant activation of RhoA (2-fold) compared to controls
that blocked by treatment with FeTPPs (Figure 4(a)). The
speciﬁc role of peroxynitrite in activating RhoA was further
examinedbycomparingactiveRhoAlevelsinBAECcultured
in high glucose (25mM) to cultures treated with exogenous
peroxynitrite (100μM). The results showed that both high
glucose and exogenous peroxynitrite can directly activate
RhoA in BAEC (Figure 4(b)). The eﬀects of high glucose in
inducing active RhoA were blunted by cotreatment of BAEC
with FeTPPs (2.5mM).
3.8. Inhibiting Peroxynitrite or RhoA Restored NO Production
and eNOS Expression in BAEC. The above results suggest
that FeTPPs enhances NO availability via increasing eNOS
expression by a mechanism that involves inhibiting RhoA
activation. In order to determine the speciﬁc contribution
of endothelium to the diabetic aortic response, we examined
the eﬀects of high glucose on NO production and eNOS
expression in BAEC. The results showed that exposure of
BAEC to high glucose (25mM) for 3 days signiﬁcantly
reduced NO production to 64% of basal control levels. Co-
t r e a t m e n tw i t hF e T P P s( 2 . 5μM) or the speciﬁc Rho-kinase
inhibitorY26732(10μM)restoredNOproductiontocontrol
levels(Figure 5).TreatmentwithY26732didnotaltertheNO
production in BAEC cultured in normal glucose (data not
shown). We next evaluated the eﬀects on eNOS expression.Experimental Diabetes Research 5
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Figure 2: FeTPPs blocked diabetes-induced oxidative stress and nitrotyrosine formation in rat vessels. Eﬀect of diabetes on oxidative and
nitrative stress in rat aortic homogenate was determined by lipid peroxides using MDA assay (a) and nitrotyrosine immunoreactivity using
slot blot (b). Both lipid peroxides and nitrotyrosine were signiﬁcantly increased in diabetic vessels. Treatment with FeTTPS blocked these
eﬀects in diabetic (D+Fe) but not in treated controls (C+Fe). Values are expressed as means ± SEM, (n = 6 in each group,
∗P <. 05 versus
c o n t r o l ) .( c ) .E ﬀect of FeTPPs on DCF ﬂuorescence. Bovine aortic endothelial cells (BAEC) were incubated with normal (NG, 5mM) and
high glucose (HG, 25mM) for 3 days (n = 5 in each group). High glucose-increased ROS formation, which was prevented by cotreatment
with FeTPPs. Values are expressed as means ± SEM,
∗P <. 05 versus control.
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Figure 3: FeTPPs restored nitric oxide production and eNOS expression in diabetic rat vessels. (a) Diabetes signiﬁcantly reduced NO
formation in rat aortic homogenate as measured by NO analyzer. Cotreatment of diabetic animals with FeTPPs restored NO back to normal
levels (n = 6 in each group). Values are expressed as means ± SEM,
∗P <. 05 versus control. (b) Real-time PCR of eNOS expression from
aortic endothelial homogenate showed that diabetes signiﬁcantly decreased eNOS expression (∼50%) of control level, and FeTPPs restored
eNOS expression to 87% of basal level (n = 5 in each group). Values are expressed as means ± SEM,
∗P <. 05 versus control.6 Experimental Diabetes Research
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Figure 4: FeTPPs inhibited diabetes-induced RhoA activation in rat vessels and BAEC. (a) Pull-down assay showed signiﬁcant increases
in active RhoA in diabetic aortic homogenate compared to that of controls that were blocked by cotreatment with FeTPPs (n = 6). Values
are expressed as means ± SEM,
∗P <. 05 versus control. (b) Bovine aortic endothelial cells (BAECs) were incubated with normal (NG,
5mM) and high glucose (HG, 25mM) for 3 days or exogenous peroxynitrite (PN, 100μM) for 18 hours (n = 4 in each group). High glucose
signiﬁcantly increased active RhoA, which was prevented by cotreatment with FeTPPs (Fe, 2.5μM). Peroxynitrite exerted similar eﬀects to
high-glucose in increasing active RhoA (∼2-fold) compared to decomposed peroxynitrite (DPN). Values are expressed as means ± SEM,
∗P <. 05 versus control.
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Figure 5: Inhibiting peroxynitrite or Rho kinase restored NO
production in BAEC. High glucose (HG, 25mM) signiﬁcantly
reduced NO production (50%) as measured by NO analyzer
in BAEC cultures compared to normal glucose (NG, 5mM).
Cotreatment with FeTPPs (Fe, 2.5μM) or with the speciﬁc Rho-
kinase inhibitor Y26732 (Y, 1μM) restored NO production in high-
glucose-maintained cultures. (n = 5) Values are expressed as means
± SEM,
∗P <. 05 versus control.
The results showed that exposure of BAEC to high glucose
(25mM) for 3 days or peroxynitrite (100μM) for 18 hours
signiﬁcantly reduced eNOS protein expression production
to 61% and 66% of basal control levels, respectively. Co-
treatment with the speciﬁc Rho-kinase inhibitor Y26732
(10μM) prevented the reduction in eNOS expression and
restored it to control levels (Figure 6).
4. Discussion
This study has demonstrated that treatment of diabetic rats
with FeTPPs, the peroxynitrite decomposition catalyst, for
4 weeks restores diabetes-induced decreases in endothelial-
dependent relaxation, reverses the decreased eNOS expres-
sion at mRNA levels, and restores NO production in the
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Figure6:InhibitingRhokinaserestoredeNOSexpressioninBAEC.
Western Blot analysis of eNOS expression showed that cultures of
BAEC maintained in high glucose (HG, 25mM) or peroxynitrite
(PN, 100μM) showed signiﬁcant reduction in eNOS expression
(40%) compared to normal glucose (NG, 5M). Cotreatment with
the speciﬁc Rho-kinase inhibitor Y26732 (Y, 1μM) restored eNOS
expression in high glucose or peroxynitrite-maintained cultures.
(n = 4) Values are expressed as means ± SEM,
∗P <. 05 versus
control.
endothelium of coronary and aortic rat vessels. Similar pro-
tective eﬀects of decomposing peroxynitrite were observed in
aortic endothelial cell cultures maintained in high glucose.
T h e s ep r o t e c t i v ee ﬀects of FeTPPs are independent of poten-
tial changes in blood glucose concentrations or metabolic
alterations related to experimental diabetes including loss of
body weight.Experimental Diabetes Research 7
Endothelial dysfunction, as indicated by impaired end-
othelium-dependent, reﬂects the inability of the vascular
endothelium to generate adequate amounts of NO and to
produce NO-mediated relaxation, which has been suggested
to be an early event in diabetic atherosclerosis and is
associatedwithcoronaryarterydiseaserisk(reviewedin[3]).
Our previous studies demonstrated that the adverse eﬀects
of diabetes on impairing endothelial function were positively
correlated with increases in oxidative stress and peroxynitrite
formation as indicated by nitrotyrosine [6, 20]. However,
the causal role of peroxynitrite in mediating endothelial dys-
functioninexperimentaldiabetesremainselusive.Thisstudy
demonstrates that coronary arteries from STZ-diabetic rats
showsigniﬁcantreductionsinNO-dependentvasorelaxation
in response to Ach, which was signiﬁcantly restored by treat-
ment of diabetic animals with FeTPPs (15mg/Kg/day, IP)
supporting a key role of peroxynitrite in mediating diabetes-
induced endothelial dysfunction. Although endothelial cells
from diﬀerent vascular beds can exhibit metabolic and
structural diﬀerences [25], diabetes has been reported to
impair NO-mediated relaxation in isolated coronary and
aortic vessels [6, 11, 20, 26–29]. Increases in oxidative
and nitrative stress have been postulated to account for
decreases in NO and subsequent formation of peroxynitrite
in coronary and aortic vessels [6, 11, 20]. In agreement,
our data show that diabetes causes oxidative and nitrative
stress in aortic vessels as indicated by increases in lipid
peroxidation, a marker for ROS and cell injury as well as
nitrotyrosine levels, a marker of peroxynitrite formation.
FeTPPs treatment substantially reduced diabetes-induced
oxidative and nitrative stress in aortic vessels.
A considerable body of evidence implicates formation
of peroxynitrite as a critical pathogenic element in diabetic
endothelial dysfunction. Our ﬁnding that FeTPPs improved
endothelial-dependent vasorelaxation while reducing oxida-
tive stress prompted us to assess the eﬀect of high glucose on
ROS formation by BAEC. Exposure of BAEC to high glucose
increased ROS levels as shown by DCF ﬂuorescence, which
was blocked by FeTPPs treatment. These data suggest that
FeTPPs attenuates diabetes-induced endothelial dysfunction
and enhances vascular relaxation by a mechanism involving
a decrease in peroxynitrite formation and hence an increase
in NO availability. This concept was supported by our
ﬁnding that FeTPPs prevents high glucose- and diabetes-
impaired production of NO in BAEC and aorta homogenate,
respectively. Decomposition catalysts, such as FeTPPs and
FP15,isomerizeperoxynitriteintonitrate[30]andha v ebeen
proven eﬀective in reducing peroxynitrite-mediated insults
in experimental models of diabetes [31–35]. Our results are
in good agreement with previous reports showing vascular
protective eﬀects of FeTPPs [23, 36–38].
To explore another mechanism by which FeTPPs could
improve diabetes-induced endothelial dysfunction, we mea-
sured eNOS mRNA levels and NO levels in the endothelium
of the aorta from various groups. Accumulating evidence
indicates that expression of eNOS is regulated by the
RhoA/ROCK pathway [14, 15]. Our data showed that
diabetes caused signiﬁcant reductions in eNOS mRNA and
NO levels, which were prevented by FeTPPs treatment.
Previous reports documented that oxidative stress and
diabetesactivateRhoA[20,21,39,40].Thelikelymechanism
by which FeTPPs upregulates eNOS is via reducing ONOO−
levels and activation of RhoA and preventing activation of its
downstream target Rho kinase, leading to the upregulation
of eNOS mRNA expression [14]. This notion is supported
by our ﬁnding that active RhoA expression has been
upregulated in diabetic aorta and in BAEC cultured in
h i g hg l u c o s e .T h ep r o t e c t i v ee ﬀects of inhibiting RhoA with
FeTPPs were most evident by restoration of NO formation.
Thus, upregulation of eNOS may have an important role
in the enhanced endothelial-dependent vasorelaxation we
observed with FeTPPs treatment. In agreement, recent
studies demonstrated reduced expression of eNOS and
NO availability in models of diabetes and oxidative stress
[11–13]. Of note, our recent studies demonstrated that a
parallel mechanism by which activation of RhoA/Rock and
subsequent upregulation of arginase expression and activity
can contribute to decreases in NO formation and endothelial
dysfunction in experimental models of diabetes [20, 41].
In summary, our data showed that FeTPPs improves
ACh-mediated vasorelaxation, enhances NO formation, and
decreases in active RhoA in diabetic rat vessels and high
glucose-treated BAEC. We propose that FeTPPs improves
diabetes-induced endothelial dysfunction through reducing
peroxynitrite formation and restoring eNOS expression and
hence increases NO production and availability.
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